Bound To Shock: Protection from Lethal Endotoxemic Shock by a Novel, Nontoxic, Alkylpolyamine Lipopolysaccharide Sequestrant
- 1 August 2007
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (8) , 2811-2819
- https://doi.org/10.1128/aac.00200-07
Abstract
Lipopolysaccharide (LPS), or endotoxin, a structural component of gram-negative bacterial outer membranes, plays a key role in the pathogenesis of septic shock, a syndrome of severe systemic inflammation which leads to multiple-system organ failure. Despite advances in antimicrobial chemotherapy, sepsis continues to be the commonest cause of death in the critically ill patient. This is attributable to the lack of therapeutic options that aim at limiting the exposure to the toxin and the prevention of subsequent downstream inflammatory processes. Polymyxin B (PMB), a peptide antibiotic, is a prototype small molecule that binds and neutralizes LPS toxicity. However, the antibiotic is too toxic for systemic use as an LPS sequestrant. Based on a nuclear magnetic resonance-derived model of polymyxin B-LPS complex, we had earlier identified the pharmacophore necessary for optimal recognition and neutralization of the toxin. Iterative cycles of pharmacophore-based ligand design and evaluation have yielded a synthetically easily accessible N 1 ,mono-alkyl-mono-homologated spermine derivative, DS-96. We have found that DS-96 binds LPS and neutralizes its toxicity with a potency indistinguishable from that of PMB in a wide range of in vitro assays, affords complete protection in a murine model of LPS-induced lethality, and is apparently nontoxic in vertebrate animal models.Keywords
This publication has 51 references indexed in Scilit:
- Molecular modeling analysis of the interaction of novel bis-cationic ligands with the lipid A moiety of lipopolysaccharideBioorganic & Medicinal Chemistry Letters, 2006
- Catabolism of polyaminesAmino Acids, 2004
- Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueInnate Immunity, 2002
- Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueInnate Immunity, 2002
- Antiendotoxin Strategies for the Prevention and Treatment of Septic ShockDrugs, 1998
- Interactions of linear dicationic molecules with lipid A: structural requisites for optimal binding affinityInnate Immunity, 1995
- Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin carrier function for albuminInnate Immunity, 1995
- Antibiotic-Induced Release of Endotoxin A therapeutic ParadoxDrug Safety, 1995
- A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian CellsScience, 1994
- Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, and Primary Amines in the Picomole RangeScience, 1972